title: Neoadjuvant chemotherapy with continuous infusion of cisplatin and fluorouracil in stage II-IV, M0 squamous cell carcinoma of the head and neck.
abstract: OBJECTIVE
  The aim of the study was to assess the activity and the toxicity of cisplatin (DDP) and fluorouracil (FU) administered by continuous infusion as neoadjuvant chemotherapy for patients with stage II-IV, M0 squamous cell carcinoma of the head and neck.
  
  
  METHODS
  Thirty previously untreated patients were submitted to chemotherapy with DDP (20 mg/m2) and FU (1000 mg/m2), both in continuous infusion for 5 days, repeated every 21 days, for a maximum of 5 cycles. Following completion of chemotherapy, the patients underwent radiotherapy; in some patients surgery was performed immediately after chemotherapy. All patients were monitored for response, time to failure, survival, treatment-related events and toxicity.
  
  
  RESULTS
  All patients were evaluated for response; after chemotherapy the complete response rate was 27% and the partial response rate 33%. Twenty-four patients underwent radiotherapy: the overall response rate was 83% (complete response 79%). After a median follow-up of 34 months, the median survival time was 22 months with a median time to failure of 15 months. Acute vascular accidents were the main and unexpected adverse events, with 2 deaths for pulmonary embolism and 1 for stroke. The response rate to the regimen does not seem to be better than that obtained with the standard combination of cisplatin bolus and fluorouracil continuous infusion. The disadvantage of the regimen is that it causes more discomfort for the patient in that it requires hospitalization.
  
  
  CONCLUSIONS
  For this reason, we believe that there are no elements for recommending the schedule as neoadjuvant treatment of patients with squamous cell carcinoma of the head and neck or as an experimental arm in a randomized trial.
authors.affiliation: Servizio di Oncologia Medica, Azienda Ospedaliera di Reggio Emilia, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Boni
authors.forename: G
authors.initials: G
authors.lastname: Moretti
authors.forename: L
authors.initials: L
authors.lastname: Savoldi
authors.forename: L
authors.initials: L
authors.lastname: Armaroli
authors.forename: W
authors.initials: W
authors.lastname: Barbieri
authors.forename: G
authors.initials: G
authors.lastname: Bisagni
authors.forename: A
authors.initials: A
authors.lastname: Caroggio
authors.forename: C
authors.initials: C
authors.lastname: Iotti
authors.forename: C
authors.initials: C
authors.lastname: Pedroni
authors.forename: A L
authors.initials: AL
authors.lastname: Manenti
authors.forename: E
authors.initials: E
authors.lastname: Rondini
authors.forename: M
authors.initials: M
authors.lastname: Sassi
authors.forename: A
authors.initials: A
authors.lastname: Zadro
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D002945:Cisplatin; D005472:Fluorouracil